NF-kappa-B Decoy oligonucleotide - Anesiva
Alternative Names: Avrina; NF-kappa-B Transcription Factor Decoy; NF-KB DecoyLatest Information Update: 06 Mar 2014
At a glance
- Originator Anesiva
- Developer Transcription Factor Therapeutics
- Class Anti-inflammatories; Antirheumatics; Oligonucleotides
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis; Inflammatory bowel diseases; Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 01 Mar 2014 Discontinued - Phase-I/II for Atopic dermatitis in Australia (Topical)
- 01 Mar 2014 Discontinued - Phase-I/II for Atopic dermatitis in Switzerland (Topical)
- 01 Mar 2014 Discontinued - Phase-I/II for Atopic dermatitis in USA (Topical)